- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Interventions
- Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Placebo delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
- Combination Product
- Lead sponsor
- Bellerophon Pulse Technologies
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 38 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Interventions
- Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device
- Combination Product
- Lead sponsor
- Bellerophon Pulse Technologies
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 43
- States / cities
- Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 35 more